This sounds more like market manipulation to me, because pharma has shown that they're capable of anything to make money. I hope they're getting looked at.

But, as Ars has reported before, the root cause of shortages of low-cost, off-patent generic drugs is well established. These drugs have razor-thin to non-existent profit margins, driven by middle managers who have, in recent years, pushed down wholesale prices to rock-bottom levels.

I have cancer. It's SUPER fun having to deal with drug shortages every fucking month, let me tell you. Nothing makes a cancer patient feel better than having to call around to local pharmacies to see who can fill a painkiller prescription. And you can't call for a refill even a single day before your current scrip is out. So they can't have it ready for you or set it aside. You run out and then you have to fucking FIGHT to not have to deal with withdrawal on top of the pain. EVERY. SINGLE. MONTH.

But you know, profits are more important than health care. So I get it. Can't have CEO's going hungry just because I'm in a little pain.

This is the best summary I could come up with:

These drugs have razor-thin to non-existent profit margins, driven by middle managers who have, in recent years, pushed down wholesale prices to rock-bottom levels.

In some cases, generic manufacturers lose money on the drugs, disincentivizing other players in the pharmaceutical industry from stepping in to bolster fragile supply chains.

The ADHD drug Adderall, for instance, has been in critical shortage since October 2022, causing millions of patients around the country to struggle to fill their prescriptions.

Although that problem has since been resolved, it came amid a significant increase in Adderall prescriptions, which spiked further during the pandemic when telehealth prescribing became more common.

But, in a joint letter with the Food and Drug Administration last August, the DEA said that, by its data, manufacturers of amphetamine products (including Adderall) only sold approximately 70 percent of their allotted quotas in 2022.

The organization has put forth policy recommendations to prevent shortages and improve supply chains, advocating for federal and regulatory changes.

The original article contains 532 words, the summary contains 161 words. Saved 70%. I'm a bot and I'm open source!